TVTX
Travere Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TVTX
Travere Therapeutics, Inc.
A company that developing therapies to treat rare disorders like nephrology, hepatology, and metabolism
3611 Valley Centre Drive, Suite 300, San Diego, CA 92130
--
Travere Therapeutics, Inc., incorporated as Desert Gatewayinc on February 8, 2008, is registered in Oklahoma.
Retrophin is a developing biopharmaceutical company dedicated to the development, acquisition and commercialization of therapeutic therapies for serious, catastrophic and rare diseases. In the United States, Retrophin is working on the development of SyntocinonTM Nasal Spray to aid postpartum milk secretion and can be used to treat schizophrenia and autism. Syntocinon Nasal Spray is currently marketed by Novartis and Sigma-Tau in Europe and other countries to help pregnant women with postpartum milk secretion. In addition, Retrophin is developing RE-034, a synthetic hormone analog consisting of 24 of the 39 amino acids contained in ACTH, for the treatment of infantile spasms and nephrotic syndrome. Retrophin is also working on re-024, a new small molecule for the potential treatment of pantothenate neurodegenerative disease. At the same time, the company is developing sparsentan, formerly known as re-021, a dual-acting angiotensin receptor and endothelin receptor for the treatment of focal segmental glomerulosclerosis. Retrophin also has several additional programs in clinical development, including re-001, for the treatment of Duchenne muscular dystrophy.
Earnings Call
Q1/2025
Estimate EPS-0.39
Actual EPS-0.19
Estimate Revenue76.86M
Actual Revenue81.73M
Contradictions Unveiled: Analyzing Travere Therapeutics' 2025 Q1 Earnings Call on FSGS Approval and Market Dynamics
May 02,2025 07:32
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.01
Actual EPS0.13
Estimate Revenue100.17M
Actual Revenue114.40M
Contradictions Unveiled: Travere Therapeutics' 2025Q2 Earnings Call Highlights Regulatory Challenges and Market Dynamics
Aug 06,2025 11:52
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
TVTX has released its 2025 Q3 earnings. EPS was reported at 0.59, versus the expected -0.09, beating expectations. The chart below visualizes how TVTX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TVTX has released its 2025 Q3 earnings report, with revenue of 164.86M, reflecting a YoY change of 162.11%, and net profit of 25.71M, showing a YoY change of 146.90%. The Sankey diagram below clearly presents TVTX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
